Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
September 09, 2021 16:20 ET
|
Gain Therapeutics
BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
September 08, 2021 09:08 ET
|
Gain Therapeutics
GT-02287and GT-02329 compounds display positive effects on GCase activityand related parameters---Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and...
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
September 08, 2021 07:29 ET
|
Gain Therapeutics
GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters--- Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and...
Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 02, 2021 16:05 ET
|
Gain Therapeutics
BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...
Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update
August 11, 2021 16:01 ET
|
Gain Therapeutics
Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology--- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other...
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 03, 2021 16:05 ET
|
Gain Therapeutics
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel...
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders
June 10, 2021 07:30 ET
|
Gain Therapeutics
BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing...
Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021 08:00 ET
|
Gain Therapeutics
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric...
Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May
May 17, 2021 08:00 ET
|
Gain Therapeutics
BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric...
Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results
May 10, 2021 16:01 ET
|
Gain Therapeutics
Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team ---Signed a multi-target...